CN Patent

CN104955952A — Lna寡核苷酸碳水化合物缀合物

Assigned to F Hoffmann La Roche AG · Expires 2015-09-30 · 11y expired

What this patent protects

本发明提供效力明显增强、治疗指数延长和毒性降低的LNA治疗药寡核苷酸碳水化合物缀合物。

USPTO Abstract

本发明提供效力明显增强、治疗指数延长和毒性降低的LNA治疗药寡核苷酸碳水化合物缀合物。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN104955952A
Jurisdiction: CN
Classification: —
Expires: 2015-09-30
Drug substance claim: No
Drug product claim: No
Assignee: F Hoffmann La Roche AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.